Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01320553 · ClinicalTrials.gov registry record · Phase 2
Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis
A Phase 2 study of Allergic Conjunctivitis, sponsored by Sun Pharma Advanced Research Company Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 122
- Enrollment target
- 1
- Study location
NCT01320553: Completed Phase 2 study of Allergic Conjunctivitis, sponsored by Sun Pharma Advanced Research Company Limited.
NCT01320553 is a Phase 2 study of Allergic Conjunctivitis that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 122 participants, roughly in line with the 129-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01320553, a Phase 2 study of Allergic Conjunctivitis, has completed, sponsored by Sun Pharma Advanced Research Company Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 122 participants
- Enrollment target
- 1
- Study location
Study Summary
The present study will test if administration of different concentrations of 1334H eyedrops will be effective in treatment of allergic conjunctivitis in people with 10 yrs of age or older.
Primary Outcome
Ocular itching evaluated by the subject at 3, 5, and 7 minutes post-challenge (0-4 scale, allowing half unit increments with 0 representing none and 4 representing Incapacitating itch with an irresistible urge to rub) at Visit 5.
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG SPARC1102 I
- DRUG SPARC1102 II
- DRUG SPARC1102 III
Study Locations (1)
Massachusetts
- ORA Inc - Andover
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2011-06 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
What the finished NCT01320553 record still lists
NCT01320553 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 129-participant average among 20 other Allergic Conjunctivitis trials with a reported enrollment target.
The record links to 1 condition, with Allergic Conjunctivitis appearing as the primary indexed condition, and to 4 interventions - of which Vehicle is the first listed.
NCT01320553 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT01320553 about?
NCT01320553 is a clinical study titled "Effect of Different Concentrations of SPARC1102 on Allergic Conjunctivitis". The present study will test if administration of different concentrations of 1334H eyedrops will be effective in treatment of allergic conjunctivitis in people with 10 yrs of age or older.
What is the current status of trial NCT01320553?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 122 participants. The study started on 2011-06. Estimated completion is 2011-09.
What conditions does trial NCT01320553 study?
This clinical trial studies the following conditions: Allergic Conjunctivitis.
What interventions are being tested in trial NCT01320553?
The interventions under investigation include: Vehicle (DRUG), SPARC1102 I (DRUG), SPARC1102 II (DRUG), SPARC1102 III (DRUG).
Who is sponsoring clinical trial NCT01320553?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01320553 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allergic Conjunctivitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01320553's enrollment target sits among peer trials
122 7th of 20 higher than 14 of 20 other Allergic Conjunctivitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Allergic Conjunctivitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
RECRUITING · Phase 2
-
Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis
RECRUITING · Phase 2
-
Evaluation of Efficacy of Coadministration of FOV1101-00 and Prednisolone Acetate in Patients With Mild Ongoing Ocular Allergic Inflammation
COMPLETED · Phase 2
-
Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis
COMPLETED · Phase 2
-
Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
COMPLETED · Phase 2
-
Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen Challenge
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia